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Due to systolic blood pressure (SBP) amplification, brachial SBP may not accurately 2 
reflect central SBP, the pressure the organs are exposed to. Patients with type 2 diabetes 3 
(T2D) have vascular irregularities that may affect blood pressure (BP) amplification 4 
and central BP indices (i.e. augmentation index [AIx] and augmentation pressure [AP]). 5 
By systematic review and meta-analysis, this study aimed firstly to determine the 6 
magnitude of central-to-brachial SBP and pulse pressure (PP) amplification in T2D 7 
compared to healthy controls and secondly, the difference in AIx and AP between the 8 
groups. Online databases were searched for published studies reporting invasive or non-9 
invasive central and brachial SBP in T2D and healthy controls up to the 20th of February 10 
2018. Random effects meta-analyses and meta-regression were used to analyse the 11 
studies. 12 
18 studies (all non-invasive; 17 radial tonometry, 1 carotid tonometry, 2 brachial 13 
oscillometry) with a total of 2,758 patients with T2D and 10,561 healthy controls were 14 
identified. There was no significant difference in SBP amplification between groups 15 
(T2D=9.9±4.7, healthy controls=9.6±4.5 mmHg, p=0.84; pooled difference=0.64 16 
mmHg, 95%CI -0.27 1.54, p=0.17) or PP amplification ratio (p=0.16). However, 17 
among these studies, central BP indices (AIx corrected for heart rate and AP) were 18 
significantly higher in T2D (p<0.05 for both). Despite a similar magnitude of central-19 
to-brachial SBP amplification, patients with T2D have increased central systolic 20 







High blood pressure (BP) is associated with adverse cardiovascular (CV) 27 
outcomes (1, 2). In clinical practice, BP is typically measured at the brachial artery by 28 
cuff (3); however, due to potential amplification in systolic BP (SBP), brachial SBP 29 
may not equal the pressure in the aorta (central SBP); the pressure to which the heart, 30 
brain and kidneys are exposed (4-6). Several methods are available to estimate central 31 
BP using non-invasive techniques (7). Indeed, recent meta-analysis of data from such 32 
techniques showed that central SBP had a significantly stronger relationship to target 33 
organ damage and increased CV disease risk, compared with brachial SBP (8). 34 
However, central SBP is influenced by a number of physiological factors. Specifically, 35 
among patients with type 2 diabetes mellitus (T2D), vascular irregularities (e.g. 36 
endothelial dysfunction (9), central (10-12) and peripheral (13) arterial stiffening) and 37 
increased CV disease risk factors (hyperlipidaemia (14)  and smoking (15)) may have 38 
a greater influence on central rather than brachial SBP, culminating in higher central 39 
systolic stress. Thus, even taking into account that cuff brachial BP methods have 40 
variable accuracy (6), there may be particular inadequacy in capturing risk related to 41 
central BP in higher risk patients (16, 17), such as those with T2D. We have previously 42 
observed similar central-to-brachial SBP amplification in patients with T2D compared 43 
to healthy controls (18), but this has never been examined by systematic review and 44 
meta-analysis. 45 
In patients with T2D, vascular dysfunction may alter the timing and direction 46 
of arterial pressure wave travel in the aorta (19, 20) and other large arteries. Waveform 47 
indices: augmentation pressure (AP); the difference between the second and first central 48 
systolic peaks, and augmentation index (AIx); AP expressed as a percentage of pulse 49 
pressure, are markers of this central systolic load that may be elevated in patients with 50 
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T2D (12, 21). Despite numerous studies examining AIx and AP in patients with T2D, 51 
it remains unclear as to whether these indices are systematically different compared to 52 
healthy individuals. The primary aim of this study was to determine the magnitude of 53 
central-to-brachial SBP and PP amplification in patients with T2D compared to 54 
apparently healthy controls and secondly, within the same dataset, to determine the 55 
difference in AIx and AP between the groups.  56 
 57 
Materials and Methods 58 
Literature search and methods. The search methods used in this study followed the 59 
Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) (22) 60 
and the Meta-analyses of Observational Studies in Epidemiology (MOOSE) (23) 61 
reporting guidelines. Two reviewers (RC and MS) independently conducted a literature 62 
search of six electronic databases (MEDLINE, CINAHL, Cochrane, EMBASE, Scopus 63 
and Web of Science) independently for studies reporting both central and brachial SBP 64 
in patients with T2D from inception up to the 20th of February 2018. The screening of 65 
titles, abstracts and full-texts were done independently by the two reviewers and then 66 
the results compared. The literature search was based on the MEDLINE search strategy 67 
(Appendix) and searches of other databases were adapted to meet the specific 68 
requirements of the database. Additionally, the reference lists of relevant original and 69 
review articles were also searched.  70 
Criteria for study inclusion. Studies were included in the systematic review if they 71 
met the following criteria: 1) a full length publication in a peer-reviewed journal; 2) a 72 
human study involving adults >18 years of age; 3) reported central and brachial SBP 73 
and diastolic BP using invasive or non-invasive techniques; 4) central and brachial SBP 74 
were measured either simultaneously or consecutively and; 5) data were reported 75 
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separately for individuals with T2D and a control (apparently healthy) group. Since the 76 
criteria for study inclusion could be derived from different types of study designs (e.g. 77 
observational case-control, longitudinal or controlled trials), there was no restriction on 78 
this criteria. Studies for the meta-analyses of AIx and AP were only included if they 79 
met the inclusion criteria for the primary aim as above. The Newcastle-Ottawa Scale 80 
(24) was used to assess the quality of included studies. The Scale awards a maximum 81 
of nine stars across three categories; selection of study participants (4 stars), 82 
comparability between groups of participants (2 stars) and exposure (3 stars). A greater 83 
number of stars indicates a higher quality study. 84 
Outcome measures. The primary outcome measure was the difference in central-to-85 
brachial SBP amplification. Secondary outcomes were central-to-brachial PP 86 
amplification, AIx, (including AIx corrected for a heart rate of 75 beats per minute 87 
[bpm]) and AP. SBP amplification was determined as brachial SBP – central SBP, and 88 
was calculated from the average brachial SBP and central SBP if not reported within 89 
individual papers. PP amplification ratio was determined by brachial PP divided by 90 
central PP. If PP (brachial or central) was not reported, it was calculated as SBP – 91 
diastolic BP (for brachial (21, 25-28) and central (21, 29) BP). Where AIx was not 92 
reported but central PP and AP were available or calculated, AIx was calculated via 93 
equation 1 below, with standard deviations calculated by the Delta method (30). In 94 
some cases, AP could not be calculated due to insufficient availability of data within 95 
the individual studies.  96 
 97 
Equation 1:  98 
AIx = (Augmentation pressure/central PP) x 100 99 
 100 
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Data extraction. Two reviewers (RC and PO) extracted data from each eligible study 101 
independently. For the systematic review the following data were extracted from each 102 
individual paper; the characteristics of the study population (including the age, sex, 103 
body mass index [BMI], insulin levels, glycated hemoglobin [HbA1c], medications, 104 
disease status and duration of diabetes), central and brachial SBP and diastolic BP, 105 
central PP, brachial PP, AIx, AP, heart rate, statistical methods and method of 106 
determining central and brachial SBP and diastolic BP (table 1). The study by Maple 107 
Brown et al. (26) was performed in two distinct populations (indigenous Australians 108 
and Australians with European ancestry) in which data were presented for both a group 109 
with T2D and non-diabetic subgroup. Therefore, these populations were treated as 110 
separate studies.  111 
Statistical analysis. Random effects analyses were performed comparing the 112 
difference in central-to-brachial SBP amplification and PP amplification ratio, AIx and 113 
AP between patients with T2D and apparently healthy controls. Five separate meta-114 
analyses were performed and studies could be included in more than one meta-analysis 115 
if the appropriate data was reported or able to be calculated. Heterogeneity between 116 
studies was reported using the I2 statistic and factors associated with heterogeneity were 117 
examined by performing meta-regression analyses to examine the effect of age, sex, 118 
BMI, heart rate, insulin levels, HbA1c, antihypertensive medication use and diabetes 119 
duration (in the diabetic group) on the difference in central-to-brachial SBP 120 
amplification between individuals with and without T2D. 121 
Sensitivity analyses were performed to assess whether three studies (29, 31, 32) 122 
that used methods other than radial tonometry calibrated with SBP and diastolic BP to 123 
determine central SBP caused any difference in effect size. Sensitivity analyses were 124 
also performed to assess whether five studies (26, 29, 33-35) in which the age the 125 
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difference between T2D and controls was >10 years influenced the effect size. Three 126 
studies (21, 31, 36) reported variance as either interquartile range or 95% confidence 127 
intervals and were therefore, converted to standard deviations for analysis. In these 128 
studies, the mean or median was within the confidence intervals or interquartile range 129 
and, therefore, the data was assumed to be normally distributed. Two studies containing 130 
data from similar cohorts were included in separate analyses, one in the analysis of 131 
central-to-brachial SBP and PP amplification (33) and one in the analysis of AIx and 132 
AP (37). All data from each individual study was reported as unadjusted. Publication 133 
bias was assessed visually via funnel plots and with Eggers test for bias.  134 
Results 135 
Literature search and systematic review. A summary of the literature search 136 
procedure and results is shown in Figure 1. The original search of six online databases 137 
revealed 20,015 original articles of which 19,906 were excluded (due to being 138 
duplications or based on review of title or abstract or both), leaving 109 potentially 139 
relevant articles that required full text reviews. 90 of these were excluded (due to 140 
required data being unavailable, unable to extract T2D data, failing to include a control 141 
group or were conference abstracts/reports), leaving 19 articles for the final systematic 142 
review (table 1) and 18 for the primary meta-analysis (one study was excluded from the 143 
meta-analysis due to duplicate data).  144 
Summary of studies included in meta-analysis. The 18 studies eligible for meta-145 
analysis included a total of 2,758 patients with T2D and 10,561 healthy controls. 146 
Patients with T2D were older (57±5 vs 51±5 years, p=0.001), of greater BMI (29.9±1.5 147 
vs 26.2±1.6 kg/m2, p=<0.001) and were more likely to be male (55 vs 48%, p=0.16; 148 
table 1) compared to apparently healthy controls. The majority of the studies estimated 149 
central SBP using radial applanation tonometry and application of a generalized transfer 150 
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function, with only three (29, 31, 32) using alternate methods (carotid applanation 151 
tonometry, Mobil-o-graph and Arteriograph). Central and brachial SBP were elevated 152 
in patients with T2D compared to healthy controls (125±9 vs 115±11 mmHg, p=0.007 153 
and 134±9 vs 125±9 mmHg, p=0.003 respectively).  154 
Central-to-brachial SBP amplification. The pooled central-to-brachial SBP 155 
amplification data from all studies showed that there was minimal difference between 156 
patients with T2D and healthy controls (0.64 mmHg, 95%CI -0.27, 1.54, p=0.17; figure 157 
2). The difference in age between individuals with and without T2D, did not explain 158 
the variance in the pooled central-to-brachial SBP amplification data (R2 = 0%) nor did 159 
the difference in sex (R2 = 0%), BMI (R2 = 0%), heart rate (R2 = 0%), or 160 
antihypertensive medication use (R2 = 0%). However, the difference in HbA1c 161 
explained 50.9% (p=0.03) of the heterogeneity in the difference in central-to-brachial 162 
SBP amplification between those with (data available in n=872) and without T2D 163 
(n=732). Further, although non-significant, the duration of diabetes explained 16.3% 164 
(p=0.15) of the variance in central-to-brachial SBP amplification between the groups.  165 
Removal of the five studies in which the age difference between patients with 166 
T2D and controls was > 10 years, made little difference to the overall pooled result 167 
(1.06 mmHg, 95% CI -0.07, 2.18, p=0.067). Central SBP was estimated from the 168 
carotid artery rather than the aorta in the study by Chirinos et al. (31); however, removal 169 
of this study from the analysis made little difference to the overall pooled result (0.6 170 
mmHg, 95%CI -0.3, 1.5, p=0.18). Furthermore, the removal of the three studies (29, 171 
31, 32) that used alternate methods to determine central SBP other than radial 172 
tonometry, did not affect the overall pooled result (0.6 mmHg, 95%CI -0.5, 1.6, 173 
p=0.28). Stratification of the pooled difference between controls and T2D in central-to-174 
brachial SBP amplification by quality, showed that in studies of low quality (scoring 175 
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<5 Newcastle-Ottawa Scale) there was little to no difference between groups (-0.06 176 
mmHg, 95%CI: -1.42 , 1.30) while there was a difference between groups in higher 177 
quality studies (1.08 mmHg, 95%CI: 0.00, 2.17). However, the difference between low 178 
and high quality studies was not statistically significant (p=0.20). 179 
Central-to-brachial PP amplification. There was no difference between patients with 180 
T2D and healthy controls in central-to-brachial PP amplification (-0.031, 95%CI -181 
0.074, 0.012, p=0.16; figure 3A). Nor was there a difference in PP amplification when 182 
the five studies with large age differences between groups were removed (-0.02, 95%CI 183 
-0.06, 0.02, p=0.34). The mean PP amplification was 1.3±0.1 mmHg in patients with 184 
T2D, and was 1.3±0.1 mmHg in healthy controls.  185 
Augmentation index and augmentation pressure. AIx was calculated using equation 186 
1 in two studies (11, 21). However, insufficient data was provided to calculate AIx in 187 
six studies (18, 27, 29, 31, 36, 38) and AP in ten studies (11, 18, 27, 29, 31, 32, 35, 36, 188 
38, 39), and therefore, these studies were excluded from this analysis. Data for AIx 189 
corrected for heart rate was only available in seven studies (27, 29, 36, 37, 39-41). All 190 
but one (32) study used radial applanation tonometry to measure AIx. Of those that did, 191 
the pooled data showed that AIx was elevated in patients with T2D compared to healthy 192 
controls (2.39%, 95% CI 0.18, 4.60, p=0.03; figure 3B), as was heart rate corrected AIx 193 
(4.34%, 95% CI 2.70, 5.97, p<0.001; figure 3C). When the study that used an alternate 194 
method to measure AIx (suprasystolic waveform analysis) was included in the analysis, 195 
the difference in AIx between those with and without T2D was borderline significant 196 
(1.98%, 95% CI -0.18, 4.15, p=0.07). However, removal of the five studies in which 197 
the age difference between patients with T2D and controls was > 10 years, rendered the 198 
difference in AIx between groups non-significant (1.53%, 95% CI -0.50, 3.55, p=0.14), 199 
but not for heart rate corrected AIx (4.97%, 95% CI 2.93, 7.02, p<0.0001).  200 
 10 
AP was significantly greater in patients with T2D compared to apparently 201 
healthy controls (2.93 mmHg, 95% CI 0.93, 4.93, p=0.004; figure 3D) and remained 202 
significant after removal of the studies where the age difference between groups was > 203 
10 years (1.87 mmHg, 95% CI 0.39, 3.35, p=0.01). 204 
Publication bias. Funnel plots (figure 4) and Egger’s test indicated that there was 205 
relatively little influence of any publication bias.   206 
 207 
Discussion 208 
The main findings of this study were; 1) no significant difference in central-to-209 
brachial SBP amplification or PP amplification ratio between patients with and without 210 
T2D; 2) markers of central systolic load (AIx and AP) were significantly increased in 211 
patients with T2D compared to apparently healthy controls and; 3) both brachial and 212 
central SBP were significantly elevated in patients with T2D compared to controls. 213 
Taken together, these findings suggest that despite no difference in SBP amplification 214 
or PP amplification ratio compared to healthy controls, patients with T2D have 215 
increased central systolic load, which cannot be identified based on a traditional 216 
brachial cuff BP measures alone. 217 
Central BP and markers of central systolic load have been shown to be elevated 218 
in populations at increased CV disease risk compared to controls, despite having similar 219 
brachial BP (11, 14, 41-44). In a large cohort of individuals from the Anglo-Cardiff 220 
Collaborative Trial, McEniery et al. (34) reported that diabetes was more strongly 221 
associated with higher central PP relative to brachial PP than other CV risk factors 222 
including hypertension, hypercholesterolemia and smoking. The discrepancy between 223 
central and brachial SBP is purported to be influenced by numerous demographic or 224 
physiological factors including age, sex, body mass index and heart rate (45-47). 225 
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Different classes of antihypertensive medications can also elicit substantial variability 226 
in SBP amplification (48, 49). Yet in our analysis, none of these potentially influential 227 
factors significantly explained the variance in SBP amplification among the study 228 
populations.  229 
The difference in mean HbA1c between individuals with and without T2D 230 
explained a large part of the heterogeneity observed in the central-to-brachial SBP 231 
amplification. However, this finding should be interpreted with caution due to the small 232 
amount of data available on HbA1c. Nonetheless, given that hyperglyceamia (known 233 
to be related to increased arterial stiffness) was well controlled in some patients with 234 
T2D (26, 29, 31) compared to others (25, 26, 28), we speculate there may have been 235 
differing degrees of arterial stiffening that could have influenced central-to-brachial 236 
SBP amplification between the studies included in the meta-analysis. Further, in 237 
patients with T2D, long term exposure to CV risk factors (hyperglycaemia (50), 238 
advanced glycation end products (51)), and the duration of diabetes (52) itself, 239 
contributes to aortic stiffness (42) via adverse changes in the elastin/collagen 240 
composition of the arterial wall (53). Hashimoto and Ito (54) hypothesized that this 241 
increase in aortic stiffness may disrupt blood flow patterns in the proximal aorta (55), 242 
exaggerate diastolic flow reversal (54) and elevate central AIx, AP and SBP. Smaller 243 
aortic root diameter, may be an additional factor further augmenting central systolic 244 
load among patients with T2D (56). Our findings support these data relating to raised 245 
AIx, AP and central SBP among patients with T2D, but the concomitant increase in 246 
brachial SBP meant there was no difference in the level of central-to-brachial SBP and 247 
PP amplification compared to healthy controls. Similarly, some of our previous work 248 
(18), implies that an individual’s level of central-to-brachial SBP amplification may be 249 
relatively fixed irrespective of BP level.  250 
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Most of the studies included in the meta-analysis estimated central SBP from 251 
radial pressure waveforms acquired by tonometry (calibrated with brachial SBP and 252 
diastolic BP) and a generalized transfer function. This approach assumes there is no 253 
SBP amplification from the brachial to radial arteries. However, significant SBP 254 
amplification in this arterial segment has been demonstrated among healthy individuals 255 
(57) as well as patients with T2D, albeit to a lesser degree in the latter (14 ± 7 vs 9 ± 8 256 
mmHg, p=0.042) (58). Failure to account for this additional SBP amplification may 257 
introduce error into estimation of central SBP (and thus, the level of SBP amplification), 258 
the magnitude of which could differ between healthy individuals and those with T2D. 259 
Another source of error among the studies examined was the use of cuff BP to calibrate 260 
waveforms, as this method has variable accuracy for determining either brachial or 261 
aortic (intra-arterial) BP (6). Lastly, diabetic-specific transfer functions to estimate 262 
central SBP may produce more accurate estimations of central SBP (59). Importantly, 263 
none of these limitations will affect AIx as a pressure independent variable. 264 
Nonetheless, more accurate non-invasive measurement of both brachial and central BP 265 
is needed to understand the true level of central-to-brachial SBP amplification in 266 
patients with T2D and healthy controls (60). 267 
Limitations. Although reviews and reference lists of included studies were searched 268 
for additional studies, we did not search for ongoing studies or grey literature, nor were 269 
study authors contacted and thus some data may have been missed. That said, the 270 
majority of the 37 studies with missing data focused on markers other than central SBP 271 
(i.e. augmentation index) as the main outcome variable and, therefore, this limitation 272 
may not have substantially influenced the findings.  273 
Summary and conclusions. This is the first systematic review and meta-analysis to 274 
compare central-to-brachial SBP and PP amplification ratio, AIx and AP between 275 
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patients with T2D and apparently healthy controls. According to conventional methods 276 
to assess these parameters, our data showed that there was no difference in central-to-277 
brachial SBP or PP amplification between the groups, despite elevated markers of 278 
central systolic load in patients with T2D. Our findings suggest that in patients with 279 
T2D, risk related to BP may not be adequately captured via a measurement of either 280 
brachial or central SBP alone and that pressure-independent parameters such as AIx 281 
may be a useful addition. 282 
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Figure legends. 481 
Figure 1. Summary of literature search and selection procedure for articles included in 482 
the systematic review and meta-analysis. BP, blood pressure; T2D, type 2 diabetes 483 
mellitus.  484 
Figure 2. Pooled estimates and 95% confidence intervals for amplification in central to 485 
brachial systolic blood pressure (SBP) in patients with type 2 diabetes mellitus (T2D) 486 
compared to healthy individuals. I2=87.3% p=0.17. The forest plot indicates that 487 
central-to-brachial SBP amplification was slightly, although not significantly, higher in 488 
patients with T2D.  489 
Figure 3. Pooled estimates and 95% confidence intervals for; (A) Amplification in 490 
central to brachial pulse pressure, I2=96.4% p=0.15; (B) augmentation index, I2=90.8% 491 
p=0.03; (C) augmentation index adjusted for a heart rate of 75 beats per minute (bpm), 492 
I2=61.0% p<0.001; (D) augmentation pressure, I2=91.7% p=0.004 493 
Figure 4. Funnel plots representing the publication bias for individual studies for each 494 
meta-analysis. (A) Central to brachial systolic blood pressure amplification; (B) central 495 
to brachial pulse pressure amplification; (C) augmentation index; (D) augmentation 496 
index corrected of heart rate of 75 beats per minute; (E) augmentation pressure. The 497 
results depict the relative absence of any publication bias.  498 
